Mibefradil (Ro405967)

InvivoChem Cat #:V3670CAS #:116644-53-2Purity >=98%

Description: Mibefradil (also known as Ro 405967 or Ro 40-5967; trade name: Posicor), a drug used for the treatment of hypertension and chronic angina pectoris, is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 uM and 18.6 uM for T-type and L-type currents, respectively. As a calcium channel blocker, the mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties. It is nonselective. On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.

References: Exp Ther Med. 2016 Mar; 11(3):1039-1044.; Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597(16)30071-6.

Related CAS#:116666-63-8 (2HCl)

-20C for 3 years in powder form

Synonym: Ro 405967; Ro-405967; Ro405967; Ro 40-5967; Ro-40-5967; Ro40-5967; trade name: Posicor.
IUPAC/Chemical Name: (1S, 2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-6-fluoro-1-isopropyl-1, 2, 3, 4-tetrahydronaphthalen-2-yl 2-methoxyacetate
InChi Key: HBNPJJILLOYFJU-VMPREFPWSA-N
InChi Code: InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28, 36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6, 8-9, 11-12, 18, 20, 28H, 7, 10, 13-17, 19H2, 1-4H3, (H, 31, 32)/t28-, 29-/m0/s1
SMILES Code: O=C(O[C]1(CCN(CCCC2=NC3=CC=CC=C3N2)C)[CH](C(C)C)C4=C(C=C(F)C=C4)CC1)COC